Esophagus carcinoma in situ

Summary

Esophagus carcinoma in situ (MONDO:0004708) is a cancer and 2 clinical trials. A subtype of in situ carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer
• Clinical trials: 2

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	esophagus carcinoma in situ
Mondo ID	MONDO:0004708
DOID	DOID:9095
ICD-10-CM	D00.1
ICD-11	218644880
NCIT	C89771
SNOMED CT	92585006
UMLS	C0154059
MedGen	56332
GARD	0024094
Anatomy (UBERON)	UBERON:0001043
Is cancer (heuristic)	yes

Also known as: carcinoma in situ of esophagus · carcinoma in situ of oesophagus · esophageal carcinoma in situ · esophageal carcinoma in situ aJCC v7 · esophagus in situ carcinoma · oesophagus in situ carcinoma · severe esophageal dysplasia · severe esophageal dysplasia aJCC v7 · stage 0 esophageal cancer · stage 0 esophageal cancer aJCC v7 · stage 0 esophageal carcinoma in situ · stage 0 esophagus carcinoma · stage 0 oesophagus carcinoma

Disease family

This is a subtype of in situ carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › neoplasm › cancer › carcinoma › in situ carcinoma › esophagus carcinoma in situ

Related subtypes (20): oral cavity carcinoma in situ, pharynx carcinoma in situ, gall bladder carcinoma in situ, adenocarcinoma in situ, nasal cavity carcinoma in situ, skin carcinoma in situ, breast carcinoma in situ, eye carcinoma in situ, lung carcinoma in situ, squamous carcinoma in situ, larynx carcinoma in situ, intestine carcinoma in situ, bladder carcinoma in situ, uterus carcinoma in situ, liver carcinoma in situ, stomach carcinoma in situ, kidney carcinoma in situ, grade III prostatic intraepithelial neoplasia, carcinoma in situ of ureter, carcinoma in situ of urethra

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 2.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	2

Top trials by phase / activity

NCT	Phase	Status	Title
NCT04170257	Not specified	UNKNOWN	Performance of White Light, NBI and Iodine Staining Endoscopy in the Diagnosis of Esophageal Lesions
NCT05208775	Not specified	UNKNOWN	A Comparative Study of Endoscopic Submucosal Dissection and Photodynamic Therapy for Early Esophageal Cancer